1 / 15

The AsthmaCo . June 2013

The AsthmaCo . June 2013. $8.9B Problem in Asthma. SALBUTAMOL (a.k.a. Albuterol) is the ONLY short-acting bronchodilator – several “me toos ” - all act via same B-adrenergic pathway $1.6B sales, 4 th most prescribed, 15 th highest selling GENERIC worldwide

yama
Download Presentation

The AsthmaCo . June 2013

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The AsthmaCo. June 2013

  2. $8.9B Problem in Asthma • SALBUTAMOL (a.k.a. Albuterol) is the ONLY short-acting bronchodilator – several “me toos” - all act via same B-adrenergic pathway • $1.6B sales, 4th most prescribed, 15th highest selling GENERIC worldwide • When Salbutamol doesn’t work… • 3.9M Emergency Department visits / yr • TREATED WITH SALBUTAMOL AGAIN! – no other options exist • $2.1B: 85% sent home after 3 hrs • $6.8B: 15% take up 1.8M hospital bed-days • >10,000 deaths worldwide • WHAT IS NEEDED: • NEW Short-Acting Bronchodilator, with NEW mechanism of action

  3. Canadian Asthma ResearchLeads to New Drug Discovery NEW mechanism of action Mucous plugs Drugs can’t get to where they are needed

  4. New Treatment: S-1226TM • Perflubron mixed with CO2-enriched air • Short-Acting Bronchodilator • Constituents are well described, safe • Constituents have previously been approved by FDA, EMA, etc… • NEW mechanism of action • Superior to Salbutamol! Circulaire II CO2 Perflubron S-1226TM

  5. Faster Than Salbutamol Tissue dye www.SolAeroMed.com/S-1226 Pre-MCh Post-MCh 0 second treatment 3 seconds treatment 1 second treatment 2 seconds treatment 4 seconds treatment

  6. More Potent and Longer-Lasting than Salbutamol

  7. Patented in Major Markets • Issued in US and Europe • Pending in other jurisdictions • Claims: • Composition of matter and method to treat • Monotherapy and in combination

  8. Markets • Emergency Department: “preceding salbutamol for acute asthma exacerbation” • Estimated at $190M Peak Sales • Less than 10% COGS – approximately $13/unit • Personal rescue device • Estimated at up to $2.9B Peak Sales • Combination drug • Estimated at $2B - $4B Peak Sales

  9. Partners • Proprietary nebulizer • Exclusive Perflubron supply • (marketed as Perflubronc® by Origen Biomedical) • Phase I Clinical Trial Phase IIa Clinical Trial Development Partner Candidates ? ?

  10. Team • Management • Experienced in the business, and top scientists • Board of Directors • Extremely successful at growing and selling respiratory medicine companies • Advisors • Highly networked, experienced

  11. Corporate Development - July 2013 - CTA@Boston Award Corp Off. in US US VCs & Partners EXIT - Acquisition Prototype Proof of Concept Market Test Exit

  12. US Expansion • Interest expressed by: • Boston Harbor Angels, Lead: Bill McPhee • Mass Medical Angels, Lead: Frank Bobe • Launchpad, Lead: Eduardo Pontoriero • Office in Cambridge, MA • Canadian Technology Accelerator • Selected in a highly competitive application process • Cambridge Innovation Center Office • Other • MIT VMS, Lead: Jerome Smith • Keiretsu Forum, Lead: Thealzel Lee

  13. S-1226™ is De-Risked Proof of Concept & Animal Studies Animal Studies Toxicity Toxicity – past studies Risk Controlled Human Efficacy Efficacy – sheep, humans Manufacturing Manufacturing - 510(k) Real World Efficacy Statistically Significant Data Regulatory Approval Pre-clinical Phase I Phase IIa Phase IIb Phase III Approval S-1226™

  14. Future Partnerships We are seeking additional strategic partnerships to help fund, develop, and commercialize S-1226™

More Related